yahoo_financeOriginal article
GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint
Phase 3positiveRisvutatug RezetecanPositive
AI Analysis
Summary
A late-stage China study for Risvutatug Rezetecan in bone cancer met its primary endpoint. The drug is licensed from GSK.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Late-stage China study met primary endpoint
Importance:7/10
Sentiment:
0.75
clinical_trialpositive_dataChinaoncologybone_cancer
Read the original article
Published by yahoo_finance on July 28, 2026 3:54 PM